by Patricia Jane Anderson. / Thesis (M. Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves 199-215). / List of Figures --- p.i / List of Tables --- p.v / List of Abbreviations --- p.viii / Abstract --- p.1 / Introduction --- p.3 / Chapter Chapter 1 - --- Literature Reviews / Chapter 1.1 --- Pharmacoanthropology and Pharmacogenetics --- p.5 / Chapter 1.1.1 --- Genetic Polymorphisms --- p.7 / Chapter 1.1.2 --- Pharmacogenetics in Asians and Caucasians --- p.13 / Chapter 1.1.2.1 --- ACE-inhibitors in Asians and Caucasians --- p.18 / Chapter 1.2 --- The Renin Angiotensin System --- p.20 / Chapter 1.2.1 --- Discovery of Inhibitors of Angiotensin Converting Enzyme --- p.24 / Chapter 1.3 --- ACE-Inhibiting Drugs --- p.25 / Chapter 1.3.1 --- Pharmacokinetics and Pharmacodynamics of Perindopril --- p.28 / Chapter 1.3.2 --- The Pharmacokinetics and Pharmacodynamics of Cilazapril --- p.32 / Chapter Chapter 2 - --- General Methodology / Chapter 2.1 --- Introduction --- p.38 / Chapter 2.2 --- Subjects --- p.49 / Chapter 2.3 --- Sample Collection --- p.40 / Chapter 2.3.1 --- Blood Samples --- p.40 / Chapter 2.3.2 --- Urine Samples --- p.40 / Chapter 2.4 --- Blood Pressure and Heart Rate Measurements --- p.41 / Chapter 2.5 --- Measurement of Transthoracic Electrical Bioimpedance --- p.41 / Chapter 2.5.1 --- Background --- p.42 / Chapter 2.5.2 --- Practical Details --- p.45 / Chapter 2.6 --- Data Analysis --- p.48 / Chapter 2.6.1. --- Analysis of Pharmacokinetic Parameters --- p.48 / Chapter 2.6.2 --- Analysis of Pharmacodynamic Parameters --- p.59 / Chapter 2.6.3 --- Analysis of Non-Invasive Haemodynamic Monitoring Data --- p.60 / Chapter 2.7 --- Statistical Analysis --- p.64 / Chapter Chapter 3 - --- The Perindopril Study / Chapter 3.1 --- Introduction --- p.67 / Chapter 3.1.1 --- Aims --- p.67 / Chapter 3.2 --- Methodology --- p.68 / Chapter 3.2.1 --- Inclusion Criteria --- p.68 / Chapter 3.2.2 --- Non-Inclusion Criteria --- p.69 / Chapter 3.2.3 --- Study Design --- p.69 / Chapter 3.2.4 --- Blood Sampling --- p.71 / Chapter 3.2.5 --- Urine Sampling --- p.71 / Chapter 3.2.6 --- Blood Pressure and Heart Rate --- p.72 / Chapter 3.2.7 --- Non-invasive Haemodynamic Monitoring --- p.72 / Chapter 3.2.8 --- Analysis of Plasma Samples --- p.73 / Chapter 3.2.9 --- Hormone and Enzyme Assays --- p.74 / Chapter 3.3 --- Data Analysis and Statistical Methods --- p.75 / Chapter 3.3.1 --- Pharmacokinetic Analysis of Plasma --- p.75 / Chapter 3.3.2 --- Pharmacokinetic Analysis of Urine --- p.75 / Chapter 3.3.3 --- Pharmacodynamic Analysis of Hormone Data --- p.75 / Chapter 3.3.4 --- Analysis of Haemodynamic Monitoring Data --- p.76 / Chapter 3.3.5 --- Statistical Analysis --- p.76 / Chapter 3.4 --- Pharmacokinetic Results --- p.77 / Chapter 3.4.1 --- Pharmacokinetics of Perindopril in Plasma --- p.77 / Chapter 3.4.2 --- Pharmacokinetics of Perindopril in Urine --- p.84 / Chapter 3.4.3. --- Pharmacokinetics of Perindoprilat in Plasma --- p.85 / Chapter 3.4.4 --- Pharmacokinetics of Perindoprilat in Urine --- p.89 / Chapter 3.5 --- Pharmacodynamic Results --- p.89 / Chapter 3.5.1 --- Angiotensin Converting Enzyme Inhibition --- p.89 / Chapter 3.5.2 --- Angiotensin I (AI) --- p.102 / Chapter 3.5.3 --- Aldosterone and Plasma Renin Activity (PRA) --- p.102 / Chapter 3.5.4 --- Plasma Protein Binding --- p.102 / Chapter 3.5.5 --- Blood Pressure and Heart Rate --- p.107 / Chapter 3.5.6. --- Safety and Tolerance --- p.108 / Chapter 3.5.7 --- Non-invasive Haemodynamic Monitoring --- p.108 / Chapter 3.6 --- Discussion --- p.120 / Chapter Chapter 4 - --- The Cilazapril Study / Chapter 4.1 --- Introduction --- p.135 / Chapter 4.1.1 --- Aims --- p.135 / Chapter 4.2 --- Methodology --- p.136 / Chapter 4.2.1 --- Inclusion Criteria --- p.136 / Chapter 4.2.2. --- Exclusion Criteria --- p.136 / Chapter 4.2.3 --- Study Design --- p.137 / Chapter 4.2.4 --- Blood Sampling --- p.139 / Chapter 4.2.5 --- Urine Sampling --- p.140 / Chapter 4.2.6 --- Blood Pressure and Heart Rate --- p.140 / Chapter 4.2.7 --- Non-Invasive Haemodynamic Monitoring --- p.140 / Chapter 4.2.8 --- Analysis of Plasma Cilazaprilat Samples --- p.142 / Chapter 4.2.9 --- Hormone and Enzyme Assays --- p.143 / Chapter 4.3 --- Data Analysis and Statistical Methods --- p.143 / Chapter 4.3.1 --- Pharmacokinetic Analysis --- p.143 / Chapter 4.3.2 --- Pharmacodynamic Analysis of Hormone Data --- p.144 / Chapter 4.3.3 --- Analysis of Non-Invasive Haemodynamic Monitoring Data --- p.144 / Chapter 4.3.4 --- Statistical Analysis --- p.146 / Chapter 4.4 --- Pharmacokinetic Results --- p.146 / Chapter 4.4.1 --- Pharmacokinetics of Cilazaprilat in Plasma --- p.146 / Chapter 4.5 --- Pharmacodynamic Results --- p.150 / Chapter 4.5.1 --- Angiotensin Converting Enzyme Inhibition --- p.150 / Chapter 4.5.2 --- Aldosterone and Plasma Renin Activity (PRA) --- p.155 / Chapter 4.5.3 --- Blood Pressure and Heart Rate --- p.155 / Chapter 4.5.4 --- Safety and Tolerance --- p.159 / Chapter 4.5.5 --- Non-Invasive Haemodynamic Monitoring --- p.160 / Chapter 4.6 --- Discussion --- p.182 / Chapter Chapter 5 - --- General Discussion --- p.188 / Appendix --- p.195 / References --- p.199 / Acknowledgements --- p.216

Digitized by Kansas Correctional Industries

Ferroptosis is a novel non-apoptotic, oxidative form of regulated cell death that can be triggered by diverse small-molecule ferroptosis inducers (FINs) and genetic perturbations. Current lack of insights into the cellular contexts governing sensitivity to ferroptosis has hindered both translation of FINs as anti-cancer agents for specific indications and the discovery of physiological contexts where ferroptosis may function as a form of programmed cell death. This dissertation describes the identification of cellular features predicting susceptibility to ferroptosis from data generated through a large-scale profiling experiment that screened four FINs against a panel of 860 omically-characterized cancer cell lines (Cancer Therapeutics Response Portal Version 2; CTRPv2 at http://www.broadinstitute.org/ctrp/). Using correlative approaches incorporating transcriptomic, metabolomic, proteomic, and gene-dependency feature types, I uncover both pan-lineage and lineage-specific features mediating cell-line response to FINs. The first key finding from these analyses implicates high expression of sulfur and selenium metabolic pathways in conferring resistance to FINs across lineages. In contrast, the transsulfuration pathway, which enables de novo cysteine synthesis, appears to plays a role in ferroptosis resistance in a subset of lineages. The second key finding from these studies identifies cancer cells in a high mesenchymal state as being uniquely primed to undergo ferroptosis. This susceptibility stems from a specific dependency of high mesenchymal-state cancer cells on the lipid hydroperoxide quenching mechanisms inhibited by FINs and is conserved across cancer cell lines of mesenchymal origin, epithelial-derived cancer cell lines that have undergone an epithelial-to-mesenchymal-transition, and patient-derived cancer cells exhibiting mesenchymal state-mediated resistance to anti-cancer therapies. The work presented herein formalizes frameworks for studying small molecule inducers of cell death through cell-line profiling. The results advance current mechanistic understanding of the cellular circuitry underlying ferroptosis sensitivity and lay the foundation for a novel therapeutic approach using ferroptosis inducers to target high mesenchymal-state cancer cells.

Thesis. 1976. Ph.D.--Massachusetts Institute of Technology. Dept. of Biology. / Microfiche copy available in Archives and Science. / Vita. / Bibliography: leaves 231-249. / Ph.D.

Recombinant giardial arginine deiminase (rADI) was characterized. The enzyme was found to have a specific activity of 12 U (mg protein)-1under at pH 7.4 and 1 mM arginine. The maximum velocity was 14.75 U (mg protein-1) and the KM was 0.167 mM. The specific activity and maximum velocity values are significantly lower than the values reported previously for giardial rADI, while the KM value is quite similar. The optimum pH for the giardial rADI was 6-9, a broad range compared to other arginine deiminases. Recombinant ADI is very specific in its binding specificity, with canavanine (KI 2.4 mM) and ornithine (KI 2.1 mM) being the only substrate analogues giving significant inhibition from the wide variety of analogues tested. None of the analogues could be shown to act as alternative substrates. The contribution of conserved, catalytic and C-terminal residues proposed by previous research towards ADI activity was investigated by site-directed mutagenesis. Mutations of catalytic site residues Asp175, Glu226, His280 and Cys424 decreased the rADI activity to below 2%. Conservative mutations showed significant activity for Asp175 to Glu175 (DE175) and Glu226 to Asp226 (ED226). Site directed mutagenesis on the conserved non-catalytic site Leu46 showed activities below 15%, with the highest activity observed for the mutation to Val46 (LV46), which differs in one CH2 to Leu46 on its side chain. The KM of the mutant LV46 was 3.64 mM while for LA46 (Leu to Ala mutation) was 1.33 mM. Excising 5, 13, 16 amino acids from the C-terminal residues resulted in activity decreasing to 0.8% of the wild type, while excising 54 amino acids caused the rADI to be insoluble. Sequence alignment of Giardia and Dictyostelium suggests a homologous area within the C-terminal extension. Site directed mutagenesis on the Tyr567 residue in this region resulted in a decrease in activity, with the highest activity observed for a Tyr to Phe mutation. Studies using specific cysteine protease inhibitors demonstrated partial protection against proteolysis of ADI against giardial proteases. Degradation of ADI by giardial proteases was more rapid at pH 6 than at pH 7.4.

In recent years, the methyl erythritol phosphate (MEP) pathway to isoprenoids has been the subject of intensive research. The interest is because isoprenoids have important roles in many cellular processes essential for the survival of several pathogenic organisms, making the inhibition of this pathway an attractive target for the drug discovery. The second enzyme in the MEP pathway is 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR). DXR is a promising target for the development of new antibiotics, antimalarials and herbicides. The overall objective of this research was a better understanding of DXR by using site-directed mutagenesis guided by crystal structure analysis and inhibition studies. One set of mutants was designed to expand the selectivity of DXR. An analog of DXP, 1,2-dideoxy-D-threo-3-hexulose 6-phosphate (1-methyl-DXP or Me-DXP), that differs from DXP by having an ethyl ketone, rather than a methyl ketone, was reported to be a weak competitive inhibitor. Using the x-ray crystal structures of DXR as a guide, a highly conserved tryptophan residue in the flexible loop was identified as a potential steric block to the use of this analog as a substrate. Four mutants of Synechocystis sp. PCC6803 DXR, named W204F, W204L, W204V and W204A, were prepared and characterized. The W204F mutant was found to utilize the analog Me-DXP as a substrate. The roles of amino acids residues shown to be in the DXR active site in the available E. coli crystal structures were also studied. Mutants at the positions Dl52, S153, E154, H155, M206 and E233, were prepared. The kinetic characterization of these mutants showed that the amino acid substitution, conservative or not, in these residues reduced the DXR catalytic activity, confirming that these are key amino acids responsible for the DXR catalytic efficiency. Inhibition studies of the E. coli DXR by fosmidomycin in the presence of Co²⁺, Mg²⁺ and Mn²⁺ showed that this inhibition is not dependent on a specific divalent cation. Inhibition of the Synechocystis sp. PCC6803 DXR by fosmidomycin and its hydroxamate and FR 900098 analogs was conducted showing that these compound are potent inhibitors of this enzyme. Fosmidomycin and FR900098 have inhibition constants in the low nM range. In addition the patterns of the progress curves for fosmidomycin, its hydroxamate analog and FR900098 were shown to be prototypical for slow, tight-binding inhibitors, as was seen for these inhibitors with the E. coli enzyme. / Graduation date: 2005

Graduation date: 1996

Graduation date: 1994

Thesis (Ph. D.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 160-187).

Thesis (Ph. D.)--University of Washington, 2003. / Vita. Includes bibliographical references (leaves 90-97).